Post-Marketing Surveillance of Euhypnos® (Temazepam): A New Hypnotic

1980 ◽  
Vol 8 (4) ◽  
pp. 295-299 ◽  
Author(s):  
L K Fowler
Keyword(s):  
Adverse Reaction ◽  
Adverse Reactions ◽  
Surveillance Study ◽  
Short Acting ◽  
Post Marketing Surveillance ◽  
Post Marketing

A post-marketing surveillance study of Euhypnos (temazepam), a new short-acting benzodiazepine hypnotic. A total of 12,350 patients requiring a sleep inducer were treated for up to 3 months with doses of 10–30 mg at night. After 2 weeks 80% of First Reports (FRs) rated Euhypnos effective and at 3 months this had risen to 92% of 3062 Second Reports (SRs). Hangover was reported in 7% of FRs and 2% of SRs but in general the drug was well tolerated with adverse reactions consisting mainly of morning nausea, headache, drowsiness and vivid dreaming. Eighty-seven per cent of FRs and 93% of SRs were ‘Clean’ reporting no hangover, adverse reaction or event of any kind.

Euhypnos® Forte, High Dose Temazepam for Resistant Insomnia: Post-Marketing Surveillance in 10,057 Patients Unresponsive to Conventional Hypnotic Dosage

1980 ◽  
Vol 8 (6) ◽  
pp. 446-452 ◽  
Author(s):  
L Keith Fowler ◽  
Maureen Schiller
Keyword(s):  
Adverse Reactions ◽  
Surveillance Study ◽  
Common Reason ◽  
High Dose ◽  
Post Marketing Surveillance ◽  
Post Marketing ◽  
Stopping Treatment

A post-marketing surveillance study of Euhypnos® Forte (temazepam 20 mg) capsules for the treatment of insomnia in 10,057 patients previously unresponsive to other hypnotics given in conventional doses. Patients were prescribed a nightly dose of 40 or 60 mg, but 95% actually took 40 mg. At 2 weeks, 89% of patients found the treatment effective, as did 95% at 3 months. Hangover, severe enough to stop treatment, occurred in less than 3% of patients, and other adverse reactions such as headache, dreams, gastro-intestinal disturbance and hangover symptoms were reported by only 6% of patients at 2 weeks and 4% at 3 months. The most common reason for stopping treatment was the patient having no further need of hypnotics. Euhypnos Forte was effective in 88% of 3,800 patients who had found nitrazepam unsatisfactory and 90% of 1,013 patients unresponsive to barbiturates.

Euhypnos® Forte (Temazepam) for Resistant Insomnia: Post-Marketing Surveillance, an Interim Report

1979 ◽  
Vol 7 (5) ◽  
pp. 379-382 ◽  
Author(s):  
L K Fowler
Keyword(s):  
Adverse Reactions ◽  
Surveillance Study ◽  
High Dose ◽  
Interim Report ◽  
Post Marketing Surveillance ◽  
Post Marketing

An interim report at six months of a post-marketing surveillance study of Euhypnos® Forte, a new high-dose temazepam preparation for the treatment of insomniac patients resistant to conventional hypnotic dosage. The analysis includes 2,043 First Reports (FRs) of two weeks treatment and 669 Second Reports (SRs) of three months treatment. More than 95% of the patients took a nightly dose of two capsules, temazepam 40 mg. Adverse reactions were generally acceptable, consisting mainly of headache, vivid dreams, gastro-intestinal disturbances and hangover effects. The preparation was effective in 88.6% of patients at two weeks and 95.8% at three months. All patients had previously found other hypnotics ineffective. Euhypnos Forte was rated effective by 85.5% of the 874 patients who had previously found nitrazepam unsatisfactory, and by 90.0% of the 201 who found barbiturates unsatisfactory.

Office-based post-marketing surveillance study on the influence of long term therapy with aripiprazole in patients with schizophrenia

2007 ◽  
Vol 40 (05) ◽  
Author(s):  
M Kungel ◽  
A Engelhardt ◽  
T Spevakné-Göröcs ◽  
M Ebrecht ◽  
C Werner ◽  
...  
Keyword(s):  
Surveillance Study ◽  
Term Therapy ◽  
Post Marketing Surveillance ◽  
Post Marketing ◽  
Long Term Therapy

Real-world longitudinal data of peginterferon beta-1a from a Swedish national post-marketing surveillance study (IMSE 6) - efficacy and safety profile

2018 ◽  
Author(s):  
Stina Kågström ◽  
Anna Fält ◽  
Selin Safer Demirbüker ◽  
Anne-Marie Landtblom ◽  
Peter Sundström ◽  
...  
Keyword(s):  
Longitudinal Data ◽  
Real World ◽  
Safety Profile ◽  
Surveillance Study ◽  
Efficacy And Safety ◽  
Post Marketing Surveillance ◽  
Post Marketing

scholarly journals Sapropterin For Phenylketonuria: A Japanese Post‐Marketing Surveillance Study

2021 ◽  
Author(s):  
Mina Tamura ◽  
Shizuka Seki ◽  
Yasuyuki Kakurai ◽  
Shuichi Chikada ◽  
Kento Wada
Keyword(s):  
Surveillance Study ◽  
Post Marketing Surveillance ◽  
Post Marketing
Sign in / Sign up

Export Citation Format

Share Document